论文部分内容阅读
目的:观察长期口服羧甲司坦片对慢性阻塞性肺疾病患者动脉氧分压、动脉二氧化碳分压、肺功能、急性发作的影响。方法:长期随访中、重度慢性阻塞性肺疾病患者92例随机分为对照组50例和治疗组42例。对照组给予戒烟、避免危险因素、康复锻炼、营养支持、家庭氧疗、心理干预等综合治疗,治疗组在对照组治疗基础上给予羧甲司坦片0.5 g/次,3次/d,口服。分别于治疗前及治疗后第6个月、第12个月测定2组肺活量、第一秒用力呼气量、动脉氧分压、动脉二氧化碳分压等指标,统计急性发作率并进行比较。结果:治疗组治疗后6,12个月肺活量、第1秒用力呼气量、动脉氧分压均较治疗前增高(P<0.05),动脉二氧化碳分压均较治疗前降低(P<0.05),对照组治疗前、后比较差异无统计学意义(P>0.05);治疗组总有效率(95.24%)优于对照组(80.00%)(P<0.05),急性发作率(52.38%),低于对照组(76.00%)(P<0.05)。结论:慢性阻塞性肺疾病患者长期口服羧甲司坦片可提高动脉氧分压,改善肺功能,降低急性发作率,提高生活质量。
OBJECTIVE: To observe the effects of long-term oral Carboxystanan tablets on arterial oxygen tension, arterial carbon dioxide partial pressure, pulmonary function and acute attack in patients with chronic obstructive pulmonary disease. Methods: In long-term follow-up, 92 patients with severe chronic obstructive pulmonary disease were randomly divided into control group (n = 50) and treatment group (n = 42). Control group was given smoking cessation, to avoid risk factors, rehabilitation exercise, nutritional support, family oxygen therapy, psychological intervention and other comprehensive treatment. The treatment group was given carbocisteine tablets 0.5 g / time, 3 times / d, oral . The levels of vital capacity, forced expiratory volume in the first second, partial pressure of arterial oxygen and partial pressure of arterial carbon dioxide were measured before treatment, 6th month and 12th month respectively after treatment. The acute attack rates were calculated and compared. Results: The vital capacity, the forced expiratory volume at 1 second and the partial pressure of arterial oxygen in treatment group were higher than those before treatment (P <0.05) at 6 and 12 months after treatment. The partial pressure of arterial carbon dioxide was lower than before treatment (P <0.05) (P <0.05). The total effective rate (95.24%) in the treatment group was superior to that in the control group (80.00%) (P <0.05), and the acute attack rate was 52.38% Lower than the control group (76.00%) (P <0.05). Conclusion: Chronic obstructive pulmonary disease patients with long-term oral carbocisteine tablets can increase arterial oxygen pressure, improve lung function, reduce the rate of acute attacks and improve quality of life.